Cancer Drug Costs: Inflation & Part D
The escalating costs of anticancer drugs under Medicare Part D are a growing concern.Discover how the average launch prices of these crucial medications have skyrocketed as 2012, with increases significantly outpacing inflation, according to new research. This report details the specific impact of these price hikes on patients and the healthcare system, revealing that observed prices in 2025 were far above inflation-adjusted rates. Even the Inflation Reduction Act‘s influence appears limited on initial launch prices. News Directory 3 helps examine the factors driving these high costs. What further solutions might emerge to make essential anticancer therapies more affordable for all?
Cancer Drug Prices Continue to Climb Despite Inflation Reduction Act
The cost of new anticancer drugs under Medicare Part D has seen a dramatic increase as 2012, with the average launch price rising by $1,694 each year. A recent study found that in 2025, the actual prices of these drugs were between 15% and 200% higher than what would be expected if prices had only risen with inflation. While the gap between observed and inflation-adjusted prices has narrowed, the increases continue to outpace inflation.
Researchers, led by Stacie B. Dusetzina, PhD, at Vanderbilt University School of Medicine in Nashville, TN, analyzed 86 branded, self-administered, molecularly targeted anticancer therapies approved by the Food and Drug Administration (FDA) between January 2010 and December 2024. They obtained drug price data from the Medicare Prescription drug plan Formulary and adjusted it for inflation.
The Inflation Reduction Act of 2022 aimed to lower drug costs by allowing Medicare to negotiate prices and requiring manufacturers to pay rebates for price increases exceeding inflation. However, the act did not address the initial launch prices of new drugs.This may incentivize manufacturers to set higher launch prices for Medicare Part D anticancer drugs, especially since the act limits out-of-pocket spending and price increases after a drug enters the market.
The study revealed a significant jump in mean monthly launch prices, from $10,954 for drugs introduced between 2012 and 2014 to $27,891 for those introduced between 2023 and 2025. Even after accounting for inflation,the mean launch price increased by $1,694 per year.
Dusetzina and colleagues wrote, “Launch prices for self-administered targeted anticancer therapies have grown precipitously, although no evidence was found of disproportionate increases in recent years… This suggests that companies were already engaging in price maximization for anticancer therapies and continued to do so after the implementation of the [Inflation Reduction Act].”
What’s next
The study’s findings suggest that while the Inflation reduction Act may eventually curb some drug price increases, further measures may be needed to address the high launch prices of new anticancer drugs and ensure affordability for patients.